An Effectiveness and Safety Study for Levofloxacin in Chronic Prostatitis
Primary Purpose
Prostatitis
Status
Completed
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
levofloxacin
levofloxacin
levofloxacin
Sponsored by
About this trial
This is an interventional treatment trial for Prostatitis focused on measuring Chronic Prostatitis, Prostatitis, levofloxacin, Levaquin
Eligibility Criteria
Inclusion Criteria:
- Males 40 years of age or older
- A clinical diagnosis of chronic prostatitis as evidenced by the following two criteria: 1. Clinical signs and symptoms of prostatitis including a soft, tender prostate without noticeable nodularity with one or more of the following signs or symptoms: painful or difficult urination, suprapubic discomfort, painful ejaculation, low back pain, perineal discomfort, urinary frequency, urinary urgency or hesitancy, decreased urinary stream, urinary retention, pain on digital rectal examination, perineal tenderness or pain, fever, chills. 2. A history of chronic prostatitis as defined as: symptomatic prostatitis - a clinical diagnosis of prostatitis having been made for at least one previous episode that lasted four weeks, or two or more episodes during the previous twelve months.
Exclusion Criteria:
- Any condition which may interfere with the evaluation of study drug including transurethral prostatectomy within six months of enrollment, the presence of a permanent transurethral catheter or a history of cystostomy or nephrostomy
- Taking hormone therapy
- Known prostatic carcinoma
- Allergy to levofloxacin, ofloxacin, ciprofloxacin, or other members of the quinolone class of antibacterials.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Active Comparator
Active Comparator
Active Comparator
Arm Label
001
002
003
Arm Description
levofloxacin 750mg tablet once daily for 2 weeks followed by 2 weeks of placebo.
levofloxacin 750mg tablet once daily for 3 weeks followed by 1 week of placebo.
levofloxacin 500mg tablet once daily for 4 weeks.
Outcomes
Primary Outcome Measures
Clinical Success
Defined as cured or improved. Response is based on the resolution of signs and symptoms at post-therapy.
Secondary Outcome Measures
Symptom Relief (Resolved)
Participants With Resolution of Prostatitis Signs and Symptoms; Resolution is defined as symptoms present (mild, moderate or severe) at Screening/Admission and absent (none) at the Posttherapy evaluation.
Clinical Success (Non-Relapse) or Failure (Relapse)
Number of Clinical Successes or Failures at the 6-Week Poststudy Telephone Contact for Participants Cured/Improved at the Posttherapy Visit
Clinical Success (Non-Relapse) or Failure (Relapse)
Number of Clinical Successes or Failures at 3 Month Poststudy Telephone Contact for Participants Cured/Improved at the Posttherapy Visit
Clinical Success (Non-Relapse) or Failure (Relapse)
Number of Clinical Successes or Failures at the 6-month Poststudy Telephone Contact For Participants Cured/Improved at the Posttherapy Visit
Total NIH-CPSI Score
National Institute of Health-Chronic Prostatitis Symptom Index numerically rates a total score (0-43) where 0 indicates no symptoms across any of the domains (pain or discomfort, urination, quality of life).
Full Information
NCT ID
NCT00402688
First Posted
November 21, 2006
Last Updated
September 2, 2013
Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Collaborators
PriCara, Unit of Ortho-McNeil, Inc.
1. Study Identification
Unique Protocol Identification Number
NCT00402688
Brief Title
An Effectiveness and Safety Study for Levofloxacin in Chronic Prostatitis
Official Title
A Multicenter, Double-Blind, Phase 3B Study to Compare the Safety and Clinical Efficacy of Levofloxacin in 750mg for 2 Weeks and Levofloxacin 750mg for 3 Weeks to That of Levofloxacin 500mg for 4 Weeks in the Treatment of Chronic Prostatitis
Study Type
Interventional
2. Study Status
Record Verification Date
September 2013
Overall Recruitment Status
Completed
Study Start Date
November 2006 (undefined)
Primary Completion Date
March 2008 (Actual)
Study Completion Date
September 2008 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Collaborators
PriCara, Unit of Ortho-McNeil, Inc.
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to compare the safety and effectiveness of levofloxacin 750 mg for 2 weeks or 750 mg for 3 weeks, compared to levofloxacin 500 mg for 4 weeks in the treatment of chronic prostatitis.
Detailed Description
The optimal duration of treatment for chronic prostatitis remains unclear. Historically, therapy for chronic prostatitis with other classes of antibacterials resulted in poor outcomes and prolonged time taking the medication. Levofloxacin belongs to the quinolone class of antibacterials and has been used to treat chronic prostatitis with 500mg of levofloxacin taken orally once a day for 4 weeks. This multicenter, double-blind (neither the patient nor the physician knows whether drug or placebo is being taken, or at what dosage), randomized (patients are assigned different treatments based on chance) study is designed to see if giving levofloxacin at a higher dose for shorter periods of time is safe and effective in treating chronic prostatitis. Safety analyses will involve the examination of the incidence, severity, and type of adverse events and changes in physical findings including vital signs and clinical laboratory tests. Patients will receive one of the following three dosing options: levofloxacin 750 mg orally administered once-a-day for 2 weeks followed by placebo once-a-day for two weeks for a total of 4 weeks, or levofloxacin 750 mg orally once-a-day for 3 weeks followed by placebo once-a-day for one week for a total of 4 weeks, or levofloxacin 500 mg orally once-a-day for 4 weeks.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Prostatitis
Keywords
Chronic Prostatitis, Prostatitis, levofloxacin, Levaquin
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
242 (Actual)
8. Arms, Groups, and Interventions
Arm Title
001
Arm Type
Active Comparator
Arm Description
levofloxacin 750mg tablet once daily for 2 weeks followed by 2 weeks of placebo.
Arm Title
002
Arm Type
Active Comparator
Arm Description
levofloxacin 750mg tablet once daily for 3 weeks followed by 1 week of placebo.
Arm Title
003
Arm Type
Active Comparator
Arm Description
levofloxacin 500mg tablet once daily for 4 weeks.
Intervention Type
Drug
Intervention Name(s)
levofloxacin
Intervention Description
750mg tablet once daily for 2 weeks followed by 2 weeks of placebo.
Intervention Type
Drug
Intervention Name(s)
levofloxacin
Intervention Description
750mg tablet once daily for 3 weeks followed by 1 week of placebo.
Intervention Type
Drug
Intervention Name(s)
levofloxacin
Intervention Description
500mg tablet once daily for 4 weeks.
Primary Outcome Measure Information:
Title
Clinical Success
Description
Defined as cured or improved. Response is based on the resolution of signs and symptoms at post-therapy.
Time Frame
Posttherapy Visit (Study Day 33-36)
Secondary Outcome Measure Information:
Title
Symptom Relief (Resolved)
Description
Participants With Resolution of Prostatitis Signs and Symptoms; Resolution is defined as symptoms present (mild, moderate or severe) at Screening/Admission and absent (none) at the Posttherapy evaluation.
Time Frame
Posttherapy Visit (Study Day 33-36)
Title
Clinical Success (Non-Relapse) or Failure (Relapse)
Description
Number of Clinical Successes or Failures at the 6-Week Poststudy Telephone Contact for Participants Cured/Improved at the Posttherapy Visit
Time Frame
Poststudy Telephone contact at 6 weeks
Title
Clinical Success (Non-Relapse) or Failure (Relapse)
Description
Number of Clinical Successes or Failures at 3 Month Poststudy Telephone Contact for Participants Cured/Improved at the Posttherapy Visit
Time Frame
Poststudy Telephone contact at 3 Months
Title
Clinical Success (Non-Relapse) or Failure (Relapse)
Description
Number of Clinical Successes or Failures at the 6-month Poststudy Telephone Contact For Participants Cured/Improved at the Posttherapy Visit
Time Frame
Poststudy Telephone Contact at 6 Months
Title
Total NIH-CPSI Score
Description
National Institute of Health-Chronic Prostatitis Symptom Index numerically rates a total score (0-43) where 0 indicates no symptoms across any of the domains (pain or discomfort, urination, quality of life).
Time Frame
Screening/Admission, On-Therapy, Week 3, Week 4, Posttherapy (Study Day 33-36)
10. Eligibility
Sex
Male
Minimum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Males 40 years of age or older
A clinical diagnosis of chronic prostatitis as evidenced by the following two criteria: 1. Clinical signs and symptoms of prostatitis including a soft, tender prostate without noticeable nodularity with one or more of the following signs or symptoms: painful or difficult urination, suprapubic discomfort, painful ejaculation, low back pain, perineal discomfort, urinary frequency, urinary urgency or hesitancy, decreased urinary stream, urinary retention, pain on digital rectal examination, perineal tenderness or pain, fever, chills. 2. A history of chronic prostatitis as defined as: symptomatic prostatitis - a clinical diagnosis of prostatitis having been made for at least one previous episode that lasted four weeks, or two or more episodes during the previous twelve months.
Exclusion Criteria:
Any condition which may interfere with the evaluation of study drug including transurethral prostatectomy within six months of enrollment, the presence of a permanent transurethral catheter or a history of cystostomy or nephrostomy
Taking hormone therapy
Known prostatic carcinoma
Allergy to levofloxacin, ofloxacin, ciprofloxacin, or other members of the quinolone class of antibacterials.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Johnson & Johnson Pharmaceutical Research & Development, L.L. C. Clinical Trial
Organizational Affiliation
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Official's Role
Study Director
Facility Information:
City
Birmingham
State/Province
Alabama
Country
United States
City
Homewood
State/Province
Alabama
Country
United States
City
Anchorage
State/Province
Alaska
Country
United States
City
Hot Springs
State/Province
Arkansas
Country
United States
City
Fresno
State/Province
California
Country
United States
City
San Diego
State/Province
California
Country
United States
City
Denver
State/Province
Colorado
Country
United States
City
New Britain
State/Province
Connecticut
Country
United States
City
New Smyrna
State/Province
Florida
Country
United States
City
Ocala
State/Province
Florida
Country
United States
City
Orlando
State/Province
Florida
Country
United States
City
Ormond Beach
State/Province
Florida
Country
United States
City
Plantation
State/Province
Florida
Country
United States
City
St Petersburg
State/Province
Florida
Country
United States
City
Tallahassee
State/Province
Florida
Country
United States
City
Tampa
State/Province
Florida
Country
United States
City
Wellington
State/Province
Florida
Country
United States
City
Columbus
State/Province
Georgia
Country
United States
City
Roswell
State/Province
Georgia
Country
United States
City
Jeffersonville
State/Province
Indiana
Country
United States
City
Des Moines
State/Province
Iowa
Country
United States
City
Shreveport
State/Province
Louisiana
Country
United States
City
Greenbelt
State/Province
Maryland
Country
United States
City
Saint Louis
State/Province
Missouri
Country
United States
City
Las Vegas
State/Province
Nevada
Country
United States
City
Marlton
State/Province
New Jersey
Country
United States
City
Albuquerque
State/Province
New Mexico
Country
United States
City
Garden City
State/Province
New York
Country
United States
City
Kingston
State/Province
New York
Country
United States
City
New York
State/Province
New York
Country
United States
City
Orchard Park
State/Province
New York
Country
United States
City
Poughkeepsie
State/Province
New York
Country
United States
City
Staten Island
State/Province
New York
Country
United States
City
Salisbury
State/Province
North Carolina
Country
United States
City
Columbus
State/Province
Ohio
Country
United States
City
Bethany
State/Province
Oklahoma
Country
United States
City
Allentown
State/Province
Pennsylvania
Country
United States
City
Bala Cynwyd
State/Province
Pennsylvania
Country
United States
City
State College
State/Province
Pennsylvania
Country
United States
12. IPD Sharing Statement
Citations:
PubMed Identifier
20394471
Citation
Paglia M, Peterson J, Fisher AC, Qin Z, Nicholson SC, Kahn JB. Safety and efficacy of levofloxacin 750 mg for 2 weeks or 3 weeks compared with levofloxacin 500 mg for 4 weeks in treating chronic bacterial prostatitis. Curr Med Res Opin. 2010 Jun;26(6):1433-41. doi: 10.1185/03007991003795030.
Results Reference
derived
Links:
URL
http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_JNJ_6051&studyid=62&filename=CR012103_CSR.pdf
Description
An Effectiveness and Safety Study for Levofloxacin in Chronic Prostatitis.
Learn more about this trial
An Effectiveness and Safety Study for Levofloxacin in Chronic Prostatitis
We'll reach out to this number within 24 hrs